

CLAIMS

1. (Original): A method for treatment of a patient suffering from major depressive disorder, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said major depressive disorder categorized as non-treatment resistant and non-psychotic.
2. (Original): A method for treatment of a patient suffering from unipolar depression, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug, said unipolar depression categorized as non-treatment resistant and non-psychotic.
3. (Original): A method for treatment of a patient having cognitive distortions with functional impairment or health hazards or of a patient undergoing smoking cessation or nicotine withdrawal, the method comprising administering to said patient an effective amount of an antidepressant in combination with an antipsychotic drug.
4. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is an atypical antipsychotic.
5. (Original): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of quetiapine, risperidone, ziprasidone, and pharmaceutically acceptable salts thereof.
6. (Original): The method of Claim 4 wherein said atypical antipsychotic drug is selected from the group consisting of olanzapine, iloperidone, Org 5222, melperone, amperozide, SM-9018, JL-13, and pharmaceutically acceptable salts thereof.
7. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is a dopamine system stabilizer.

8. (Original): The method of Claim 7, wherein said dopamine system stabilizer is aripiprazole, or pharmaceutically acceptable salts thereof.

9. (Original): The method of Claims 1, 2, or 3, wherein said antipsychotic drug is an antipsychotic administered at a low dose.

10. (Original): The method of Claim 9, wherein said antipsychotic drug is selected from the group consisting of perphenazine, trifluoperazine, zotepine, flupenthixol, amisulpride, and sulpiride.

11. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of serotonin reuptake inhibitors, a selective norepinephrine reuptake inhibitors, combined action SSRI/SNRI, serotonin-2 antagonist/reuptake inhibitors, an antidepressant with alpha-2 antagonism plus serotonin-2 and serotonin-3 antagonism, an antidepressant with serotonin/norepinephrine/dopamine reuptake inhibition and an antidepressant with norepinephrine and dopamine reuptake inhibition.

12. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is selected from the group consisting of 5-HT-1alpha antagonist, 5-HT-1beta antagonist, 5-HT1A receptor agonists, 5-HT1A receptor agonists and antagonists, 5-HT2 receptor antagonists, viloxazine hydrochloride, dehydroepiandrosterone, NMDA receptor antagonists, AMPA receptor potentiators, substance P antagonists/ neurokinin-1 receptor antagonists, nonpeptide Substance P antagonist, neurokinin 2 antagonists, neurokinin 3 antagonists, corticotropin-releasing factor receptor antagonists, antiglucocorticoid medications, glucocorticoid receptor antagonists, cortisol blocking agents, nitric oxide synthesise inhibitors, inhibitors of phosphodiesterase, enkephalinase inhibitors, GABA-A receptor agonists, free radical trapping agents, atypical MAOI's, selective MAOI inhibitors, hormones, folinic acid, leucovorin, tramadol, and tryptophan.

13. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is a selective serotonin reuptake inhibitor.

14. (Currently amended): The method of Claims 11–~~or~~–13, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

15. (Currently amended): The method of Claims 11–~~or~~–13, wherein the antidepressant is clomipramine.

16. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is risperidone.

17. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is quetiapine.

18. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is olanzapine.

19. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is aripiprazole.

20. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is risperidone.

21. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is quetiapine.

22. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is olanzapine.

23. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is aripiprazole.

24. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is risperidone.

25. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is quetiapine.

26. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is olanzapine.

27. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is aripiprazole.

28. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is risperidone.

29. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is quetiapine.

30. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is olanzapine.

31. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is aripiprazole.

32. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluoxetine and said antipsychotic is ziprasidone.

33. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is paroxetine and said antipsychotic is ziprasidone.

34. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is sertraline and said antipsychotic is ziprasidone.

35. (Original): The method of Claims 1, 2, or 3, wherein said antidepressant is fluvoxamine and said antipsychotic is ziprasidone.

36. (Original): The method of Claims 1, 2, or 3, wherein the antipsychotic is selected from the group consisting of risperidone, quetiapine, olanzapine, ziprasidone and aripiprazole, and the effective amount is from 0.5mg to 4mg for risperidone, from 25mg to 400mg for quetiapine, from 2.5mg to 10mg for olanzapine, from 10mg to 40 mg for ziprasidone, and 2.5mg to 15 mg for aripiprazole.

37. (Original): The method of Claims 1, 2, or 3, wherein an effective amount of the antidepressant is its recommended therapeutic dose, or its effective starting dose.

38. (Original): The method of Claims 1, 2, or 3, wherein the administration is oral.

39. (Original): The method of Claims 1 or 2, wherein treatment is given as initial treatment or as soon as possible, or upon presentation to a physician or a health care provider.

40. (Cancelled)

41. (Original): The method of Claims 1 or 2, wherein treatment is given for preventing suicide.

42. (Original): The method of Claims 1 or 2, wherein treatment is given for preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against or remedying the development of tolerance toward the antidepressant, to provide a neuroprotective effect, to avoid a paradoxical effect of

antidepressant to sensitize patients to depression, to avoid or treat worsening of depression from the antidepressant, to treat residual symptoms of depression, or for preventing the development of delusional/psychotic depression.

43. (Original): The method of Claims 1 or 2, wherein treatment is given as initial treatment or as soon as possible, or upon presentation to a physician or a health care provider for preventing suicide.

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Currently amended): The method of Claims 1-16 to 35, wherein treatment is given for preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against or remedying the development of tolerance toward the antidepressant, to provide a neuroprotective effect, to avoid a paradoxical effect of antidepressant to sensitize patients to depression, to avoid or treat worsening of depression from the antidepressant, to treat residual symptoms of depression, or for preventing the development of delusional/psychotic depression.

49. (Original): The method of Claim 3, wherein treatment is given for cognitive distortion(s), when the cognitive distortion(s) lead to functional impairment, or serious health hazard.

50. (Original): The method of Claim 3, wherein treatment is given for smoking cessation or nicotine withdrawal.

51. (New): The method of Claim 13, wherein the antidepressant is selected from the group consisting of fluoxetine, norfluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, bupropion, nefazodone, mirtazapine, venlafaxine, duloxetine, milnacipran, reboxetine, zimelidine, indalpine, gepirone, femoxetine, alaproclate and pharmaceutically acceptable salts thereof.

52. (New): The method of Claim 13, wherein the antidepressant is clomipramine.

53. (New): The method of Claim 2, wherein treatment is given for preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against or remedying the development of tolerance toward the antidepressant, to provide a neuroprotective effect, to avoid a paradoxical effect of antidepressant to sensitize patients to depression, to avoid or treat worsening of depression from the antidepressant, to treat residual symptoms of depression, or for preventing the development of delusional/psychotic depression.

54. (New): The method of Claim 3, wherein treatment is given for preventing disease progression, modifying the course of depression, delaying/preventing relapse, preventing the recurrence of depression, protecting against or remedying the development of tolerance toward the antidepressant, to provide a neuroprotective effect, to avoid a paradoxical effect of antidepressant to sensitize patients to depression, to avoid or treat worsening of depression from the antidepressant, to treat residual symptoms of depression, or for preventing the development of delusional/psychotic depression.